Ketorolac Tromethamine Ophthalmic Solution, 0.5%, 5 mL, Rx Only, Sterile, Manufactured by: Apotex...
FDA Drug Recall #D-0677-2025 - Class II, September 5, 2025
Recall Summary
| Recall Number | D-0677-2025 |
| Classification | Class II - Moderate risk |
| Date Initiated | September 5, 2025 |
| Status | Ongoing |
| Voluntary | Voluntary: Firm initiated |
Recalling Firm
| Firm | Apotex Corp. |
| Location | Weston, FL |
| Product Type | Drugs |
| Quantity | 493,468 bottles |
Product Description
Ketorolac Tromethamine Ophthalmic Solution, 0.5%, 5 mL, Rx Only, Sterile, Manufactured by: Apotex Inc., Richmond Hill, Ontario, Canada, L4C 5H2, Manufactured for: Apotex Corp., Weston, FL 33326, NDC 60505-1003-1.
Reason for Recall
Lack of Assurance of Sterility; atypical weight loss due to improper bottle sealing leading to potential sterility concerns
Distribution Pattern
Nationwide in the US
Lot / Code Information
Batch # VA0444, exp. date 01/2026 Batch # VA4608, exp. date 01/2026 Batch # TZ7016, exp. date 12/2025 UPC on Bottles: (01)0(03)60505100316 UPC on Cartons: 360505100316
Other Recalls from Apotex Corp.
| Recall # | Classification | Product | Date |
|---|---|---|---|
| D-0510-2026 | Class II | Desmopressin Nasal Spray, USP, 10 mcg/0.1 mL, 5... | Apr 8, 2026 |
| D-0407-2026 | Class II | Brimonidine Tartrate/Timolol Maleate Ophthalmic... | Mar 5, 2026 |
| D-0676-2025 | Class II | Brimonidine Tartrate/Timolol Maleate Ophthalmic... | Sep 5, 2025 |
| D-0496-2025 | Class II | Brimonidine Tartrate/Timolol Maleate Ophthalmic... | May 28, 2025 |
| D-0494-2025 | Class II | Ketorolac Tromethamine Ophthalmic Solution, 0.5... | May 28, 2025 |
Frequently Asked Questions
Injectable drugs and eye drops must be completely free of microbial contamination because they bypass the body's natural defenses. A contaminated injectable can introduce bacteria or fungi directly into the bloodstream, potentially causing sepsis, meningitis, or localized infections, all of which can be life-threatening. Contamination of sterile products almost always results in a Class I recall. If you received an injectable drug from a recalled lot, contact your healthcare provider immediately, even if you feel well, as some infections can have delayed onset.
Not necessarily. Many drug recalls are initiated because of quality system failures or test results that suggest a product might not meet specifications, even if no patients have reported harm. The FDA uses a precautionary approach: if there is reason to believe quality standards were not met, a recall is required regardless of whether adverse effects have been reported. Class I recalls typically involve a reasonable probability of harm; Class II recalls may cause temporary health issues; Class III recalls are for products unlikely to cause adverse health consequences but that still violate regulations.
Pharmacies typically receive recall notices directly from drug wholesalers and manufacturers within days of the recall being announced. Your pharmacist can look up whether any product in your prescription history matches a recalled lot number. For current recalls, the FDA publishes updates at FDA.gov/safety/recalls-market-withdrawals-safety-alerts and sends MedWatch email alerts for significant drug safety issues. You can sign up for MedWatch alerts at FDA.gov. Most major pharmacy chains also have their own recall notification systems that automatically alert pharmacists when a recalled product is in their inventory.
What Should You Do?
Stop using this medication if affected by this recall. Contact your pharmacist or prescribing doctor immediately for guidance. Do not flush medications, use a drug take-back program.